Abstract
Introduction

Multiple sclerosis (MS) is a central nervous system (CNS) disease characterized by inflammation, demyelination and neurodegeneration. Autoimmune activity directed against components of the myelin sheath is considered to be the major process underlying MS pathology
. MS is a heterogeneous disease, which is characterized in most cases by an initial relapsing-remitting (RR) course, followed by gradual accumulation of disability. [2] . Proteolytic activity is involved in both these processes: in generation of myelin-derived epitopes and in degradation of the extracellular matrix (ECM) components, required for the extravazation process. In addition, as demonstrated for matrix metalloproteinases (MMPs), proteolytic activity also contributes to regulation of cytokine activity which is part of the inflammatory response and autoimmunity [3, 4] . [5] [6] [7] [8] [9] . [10] . In immune cells, cathepsins, such as cathepsins S and L, play a key role contributing to antigen presentation by the MHC class II molecules, thorough their role in processing of antigenic peptides, and their participation in the stepwise degradation of the invariant chain (Ii) [11] [12] [13] . Regulation of Ii levels by cathepsin S can also affect the migration of immune cells, such as dendritic cells [14] . The retained activity of some cathepsins at physiological PH [10] , and their ability to degrade ECM components, such as laminin, fibronectin and collagen [15] , may contribute to their effects on cell invasiveness and motility [16] [17] [18] . The involvement of cathepsins, particularly cathepsin B, in thymocyte and mature T-cell apoptosis is another path of activity by which cathepsins affect immune functions [19] . Accordingly, cathepsin activity has been implicated in a variety of immune-mediated disorders, such as experimental autoimmune myasthenia gravis [20] , Sjögren syndrome [21, 22] , atherosclerosis and rheumatoid arthritis [15, 23, 24] .
The auto-reactive immune response, which includes processing and presentation of the self-antigen by the antigen-presenting cells, and the massive infiltration of activated leucocytes through the blood-brain barrier (BBB) into the CNS, are critical events in MS pathogenesis
MS treatments, such as glucocorticoids (GCs) and interferon-␤ (IFN-␤), reduce BBB permeability, down-regulate the expression of proteins involved in antigen presentation [such as major histocompatibility complex (MHC) class II molecules] and down-regulate MMPs
The cathepsin family of papain-like cysteine proteases is mainly involved in metabolic degradation of peptides and proteins in the lysosome
Several observations suggest that cysteine cathepsins may also play a role in MS. Predominant autoantigens in MS, the myelin basic protein (MBP) and the myelin oligodendrocyte glycoprotein are targets for processing by cathepsin S in antigen-presenting cells [11, 25] and increased cathepsin B activity was observed in MS lesions, CSF and PBMCs [26] [27] [28] . Additional evidence from a study using an animal model of demyelination complements these findings by demonstrating the abnormal expression of several cathepsins and cystatins [29] . Finally, pharmacogenetics studies of our team and others identified single nucleotide polymorphisms within the CTSS gene (encoding cathepsin S) that were associated with the clinical response to the approved immunotherapies for relapsing MS -glatiramer acetate [30] and IFN-␤ [31] .
The 
Materials and methods
Study population
Patients with clinically and laboratory definite RR MS according to
McDonald's criteria [32] 
Relative quantitative analysis of RNA expression
Peripheral blood leucocytes (PBLs) were prepared from blood samples and RNA extracted as previously described [5] The ratios of serum cathepsin S to cystatin in the MS relapse group were significantly increased compared to the remission and control groups, paralleling the differences observed for the cathepsin S protein itself (56% and 59% increase; P ϭ 0.027 and P ϭ 0.01, respectively) (Fig. 1C) .
GC effects on cathepsins and cystatins expression at relapse
Following the observation that in the relapse state, cathepsin S RNA and serum protein levels are higher, we evaluated the effects of GC therapy, which reduces the relapse severity and duration in MS, on expression levels of cathepsin S, cathepsin B, cystatin C and cystatin B.
GC treatment led to a significant reduction in the RNA levels for all four genes (44% decrease, P ϭ 6 ϫ 10 Ϫ6 for CTSS; 16% decrease, P ϭ 0.03 for CTSB; 27% decrease, P ϭ 0.0001 for CSTC; and 36% decrease, P ϭ 2 ϫ 10 Ϫ5 for CSTB) (Fig. 2A) .
Following GC treatment, serum protein levels (Fig. 2B) (Fig. 2C ).
IFN-␤-mediated modulation of cathepsins and cystatins expression
IFN-␤ therapy led to a significant but mild increase in the RNA levels of CTSB (16% increase, P ϭ 0.03), and a much more prominent and significant increase in the cystatin genes CSTC (48% increase, P ϭ 0.011) and CSTB (44% increase, P ϭ 0.004) in PBLs (n ϭ 16) (Fig. 3A) .
CTSS RNA levels did not change significantly following IFN-␤ treatment; however, paired analysis revealed a decrease in serum cathepsin S protein levels following IFN-␤ treatment in the majority of patients (19/25 patients displayed decreased levels, overall 16% decrease of median, P ϭ 0.006) (Fig. 3B). Notably, IFN-␤ treatment did not affect significantly either pro-cathepsin B or cystatin C serum protein levels. Thus, the overall effect of IFN-␤ therapy was a small but significant decrease of the cathepsin S to cystatin C ratio in the serum by 16% (a decrease was observed in 21/25 treated
patients, P ϭ 0.0008) (Fig. 3C ). Figure 4A ; however, this trend did not reach statistical significance. Differences for CTSB, CSTB (not shown) and CSTC (Fig. 4A) (Fig. 4C) .
IFN-␤ response phenotype and cathepsin S expression levels
Following the pharmacogenetics study which reported association of the CTSS gene with IFN-␤ response in MS [31], and our © 2011 The Authors Journal of Cellular and Molecular Medicine © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
Fig. 1 Cathepsin S levels in RNA from PBLs and sera of MS patients compared to healthy controls. (A) CTSS mRNA levels in healthy controls (n ϭ 18); MS patients in remission (n ϭ 24) and patients in relapse (n ϭ 30) were assessed by real-time PCR. The 2 Ϫ⌬C
T values shown are relative to GAPDH as a reference gene. (B) ELISA analysis of cathepsin S serum protein levels in healthy controls (n ϭ 20), MS patients in remission (n ϭ 25) or relapse (n ϭ 18) (both groups without immunomodulatory treatment). (C) Ratio of serum cathepsin S/cystatin C in healthy controls (n ϭ 20), MS remission (n ϭ 25) and MS relapse (n ϭ 18) groups. Medians are depicted by horizontal bars. observation that IFN-␤ seems to reduce cathepsin S serum protein levels (above), we assessed cathepsin S and its inhibitors' expression with respect to the IFN-␤ treatment response phenotype in the patient cohort. Pre-treatment levels of cathepsin S were higher in RNA from PBLs of patients classified as 'good responders' (n ϭ 12) compared to the 'others' group (n ϭ 11), shown in
Notably, the effect of IFN-␤ treatment of reducing the cathepsin S/cystatin C ratio, which we observed in the whole cohort analysis, upon stratification of the cohort by IFN-␤ response phenotype, appears to be confined mainly to the 'good responder' phenotype group (P ϭ 0.009). Cathepsin B levels were not asso-© 2011 The Authors Journal of Cellular and Molecular Medicine © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
Fig. 2 Modulation of cathepsin and cystatin expression by GC therapy in PBLs and serum during the MS relapse. (A) Relative RNA expression levels before and at day 7, following a 6 day IV course of GC treatment were quantified by 2
Ϫ⌬⌬C
T values, n ϭ 27 (except for CSTB n ϭ 26). (B) Serum protein levels in day 7 following therapy initiation are depicted relative to pre-treatment values at relapse for cathepsin S (n ϭ 26), pro-cathepsin B (n ϭ 23), cystatin C (n ϭ 26). (C) Changes in the ratios between the proteases and the inhibitor cystatin C in the serum following GC treatment. Horizontal bars: median of fold changes of post-treatment relative to pre-treatment ratios.
Fig. 3 IFN-␤ effects on cathepsins and cystatins expression in PBLs and sera from MS patients in remission. (A) Expression levels of cathepsins and cystatins following a 3-6 month period of IFN-␤ treatment and relative to pre-treatment levels, quantified by 2 Ϫ⌬⌬C
T values; n ϭ 16. (B) Cathepsin S serum protein levels before and following a 3-6 month period of IFN-␤ treatment were analysed by ELISA (n ϭ 27). (C) Ratios between the serum levels of the proteases and the cystatin C inhibitor. Horizontal bars: median of fold changes of during treatment relative to pre-treatment ratios. ciated with IFN-␤ response and neither was its ratio to cystatin C (data not shown).
Discussion
In the present study we analysed the modulation of expression of cathepsins S and B and their inhibitors cystatins C and B in patients with MS. We report higher levels of the protease cathepsin S in MS patients during the relapse state, in RNA from PBLs and in serum proteins, in comparison with healthy individuals. RNA levels of the endogenous cathepsin inhibitors cystatins B and C were also increased in the relapse state. Therefore, although the transcript levels of cathepsin S increased in PBLs in MS patients, their biological effects may be kept in check by the concomitant increase of the cystatin inhibitors' transcripts. In the serum, however, the balance between the cathepsin S and cystatin C levels was shifted upwards in the relapse state, mainly as a result of the increase in the levels of cathepsin S.
These findings are consistent with the known functions of cathepsin S in immune activity, and with reports of elevated cathepsin S levels observed in other immune-mediated diseases, as well as in animal models of autoimmune conditions [20, 21, 24, 29, 36, 37] , and with the reported inhibition of autoimmune states by specific cathepsin S inhibitors [21, 38] . Notably, studies to date have been inconsistent with respect to reports of cystatin C levels in MS patients, and were based on CSF findings in the CSF [39] [40] [41] [42] [43] [44] . [50] . Increased extracellular proteolysis is a known element in the pathogenesis of MS and has been described extensively for the MMP family of proteases [4, 5, [51] [52] [53] 
. The results of the present study suggest that MS disease state is not correlated with changes in cystatin C serum levels. Both GCs and IFN-␤, immunosuppressive and immunomodulatory treatments used in the management of MS, decreased serum cathepsin S levels, with an inverse effect on the inhibitor cystatin C serum levels. The net effect of these antiinflammatory therapies, and particularly that of GC, was to shift the cathepsin S/cystatin C ratios towards those observed in the remission state and towards norms observed in the healthy controls group, suggesting an overall decrease of the proteolytic capacity in the serum. Similar effects of GCs on cathepsin S and cystatin C have been reported in patients with asthma and in in vitro studies
